Eli Lilly's Chief Executive Officer reported that Foundayo, a GLP 1 pill, is currently being taken by one third of all new patients entering this specific medication market. The pharmaceutical company is actively increasing its manufacturing capabilities and production for Foundayo to support this growing patient uptake. This ramp up in production underscores the drugmaker's strategic focus on expanding its share in the competitive GLP 1 pill segment.
The company is making concentrated efforts to narrow the lead held by Novo, a competitor that established an earlier market presence in the GLP 1 pill sector. Eli Lilly aims to strengthen its competitive position and secure a larger portion of the market by enhancing Foundayo's availability. This move is part of a broader strategy to catch up to its rival in this therapeutic area.